Joachim Yahalom

Medicine · Health Sciences

83h-index26.9kcitations517works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(336), CNS Lymphoma Diagnosis and Treatment(143), Lung Cancer Treatments and Mutations(81), Viral-associated cancers and disorders(71), Chronic Lymphocytic Leukemia Research(56)

Publications512 total

Bridging Radiotherapy Improves Systemic Inflammation before CAR T-cell Therapy (CAR-T)
Transplantation and Cellular Therapy·2026
Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, Phase 2 trial
Blood·2025Open Access
A multicenter real-world analysis of combined chemotherapy followed by consolidative radiation versus chemotherapy alone in the management of early-stage Hodgkin lymphoma – the HODGKIN25 study
Blood·2025Open Access
RADT-84. LOW-DOSE WHOLE BRAIN RADIOTHERAPY AS AN EFFECTIVE CONSOLIDATION STRATEGY IN SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Neuro-Oncology·2025Open Access
The Influence of Dose on Response Duration of Total Skin Electron Beam Therapy (TSEBT) for Mycosis Fungoides in the Modern Era of TSEBT Dose Reduction
International Journal of Radiation Oncology*Biology*Physics·2025
Progression Patterns by Positron Emission Tomography (PET) for Relapsed/Refractory Multiple Myeloma (RRMM) after CAR T cell Therapy: Potential role for Radiotherapy (RT)?
Clinical Lymphoma Myeloma & Leukemia·2025
Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis
Haematologica·2025· 1 citedOpen Access
276 | MODERN TRENDS AND OUTCOMES OF THE INCREASING UTILIZATION OF RADIATION THERAPY IN MANTLE CELL LYMPHOMA
Hematological Oncology·2025Open Access
853 | CTEP TRIAL 10590, NORM: NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA PATIENTS TREATED IN A RANDOMIZED PHASE II TRIAL WITH EITHER RITUXIMAB OR MOSUNETUZUMAB
Hematological Oncology·2025Open Access
395 | TOTAL SKIN ELECTRON BEAM THERAPY FOR MYCOSIS FUNGOIDES IN THE MODERN ERA OF TSEBT DOSE REDUCTION AND DIVERSIFIED SYSTEMIC THERAPY
Hematological Oncology·2025Open Access
407 | RADIATION THERAPY FOR OLIGO‐RELAPSED/PROGRESSIVE DISEASE POST‐STEM CELL TRANSPLANT FOR MULTIPLE MYELOMA: FACTORS ASSOCIATED WITH FAVORABLE OUTCOMES
Hematological Oncology·2025Open Access
268 | THE EFFECT OF TP53 MUTATIONS ON THE LOCAL RESPONSE OF MANTLE CELL LYMPHOMA TO RADIATION THERAPY
Hematological Oncology·2025Open Access
Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study
Blood Advances·2025· 5 citedOpen Access
Treatment of primary esophageal lymphomas: A review
Frontiers in Oncology·2025Open Access
Electronic patient-reported outcomes for CAR T-cell therapies
The Lancet Oncology·2025
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma
Journal of Clinical Oncology·2024· 14 citedOpen Access
Consolidation Regimen and Cerebral Atrophy in Patients With Primary Central Nervous System Lymphoma
International Journal of Radiation Oncology*Biology*Physics·2024· 1 citedOpen Access
Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma
Leukemia & lymphoma/Leukemia and lymphoma·2024· 1 citedOpen Access
Supplementary Figure S2 from Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma
2024Open Access
Data from Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma
2024Open Access
page 1 of 26Next →

Frequent Co-authors

Andrew D. Zelenetz(14), Craig H. Moskowitz(11), Lauren E. Abrey(9), Lisa M. DeAngelis(9), Ariela Noy(8), David J. Straus(8), Carol S. Portlock(7), Lena Specht(6), Richard T. Hoppe(6), Steven M. Horwitz(6), Stephen D. Nimer(6), Tarun Kewalramani(5), Alison J. Moskowitz(5), Beryl McCormick(5), Andrea K. Ng(4), Ranjana H. Advani(4), Leo I. Gordon(4), Julie M. Vose(4), Jing Qin(4), Paul A. Hamlin(4)